Novo Nordisk diabetes research funding opportunity, due Aug. 1

Novo Nordisk R&D has renewed its research award program which helps new and established scientists substantiate early innovation in the area of diabetes and obesity research. Areas of research supported by the awards include (1) new biologic therapeutics and targets amenable to biologics therapeutics or novel effects of known biologics in the field of Type 1 Diabetes and Type 2 Diabetes, including microvascular complications and obesity, and (2) protein-based science technologies including oral and injection delivery concepts. Please note that only non-clinical proposals will be accepted. For more information or to apply for funding, please go to www.novonordisk-us.com/innovation.

For questions, please contact Brittany Sale.

Bookmark and Share

Comments are closed.

About the Author

Welcome to the Research News Blog

Welcome to the Research News Blog

OHSU Research News is your portal to information about all things research at Oregon Health & Science University. Visit often for updates on events, discoveries, and important funding information.

Read more

Participation Guidelines

Remember: information you share here is public; it isn't medical advice. Need advice or treatment? Contact your healthcare provider directly. Read our Terms of Use and this disclaimer for details.

Categories

Archives